


In re: Opara
Serial No.: To Be Assigned
Filed: January 21, 2002
Page 4

Remarks

The changes made to the claims above are shown in the attached "version with markings to show changes made".

It is respectfully submitted that this application is in condition for substantive examination, which action is respectfully requested.

Respectfully submitted,


Kenneth D. Sibley
Registration No. 31,668




20792
PATENT TRADEMARK OFFICE

CERTIFICATE OF EXPRESS MAILING

Express Mail Label No. EV015809085US

Date of Deposit: January 23, 2002

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box Patent Application, Commissioner For Patents, Washington, DC 20231.


Vickie Diane Prior
Date of Signature: January 23, 2002

#228811

Version with Markings to Show Changes Made

6 (amended). A product [method] according to claim [1] 77, where said microcapsule comprises a polysaccharide gum surrounded by a semipermeable membrane.

7 (amended). A product [method] according to claim [1] 77, where said microcapsule comprises alginate in combination with polylysine, polyornithine, and combinations thereof.

8 (amended). A product [method] according to claim [1] 77, wherein said microcapsule has an internal cell-containing core of alginate.

9 (amended). A product [method] according to claim 8 wherein said internal cell-containing core of alginate is gelled.

10 (amended). A product [method] according to claim [1] 77, wherein said internal cell-containing core of alginate is not gelled.

11 (amended). A product [method] according to claim [1] 77, wherein said microcapsule has a diameter of from about 50 μm to about 2 mm.

12 (amended). A product [method] according to claim [1] 77, wherein said microcapsule has a diameter of from about 200 μm to about 1000 μm .

13 (amended). A product [method] according to claim [1] 77, wherein said microcapsule has a diameter of from about 300 μm to about 700 μm .

77 (amended). A microencapsulated islet cell product comprising microcapsules containing isolated living pancreatic islet cells therein, said microencapsulated islet cells exhibiting a weight gain of not more than 10 percent by weight over a period of one month in

In re: Opara
Serial No.: To Be Assigned
Filed: January 21, 2002
Page 6

physiological saline solution at 37 degrees Celsius [(exhibiting the durability thereof)] and exhibiting at least 150 percent basal insulin secretion in response to 16.7 milliMolar glucose challenge in Krebs-Ringer physiological solution at pH 7.4 after said period of one month.

84 (new). A microencapsulated islet cell product comprising microcapsules containing isolated living pancreatic islet cells therein, said microencapsulated islet cells exhibiting a weight gain of not more than 10 percent by weight over a period of one month in physiological saline solution at 37 degrees Celsius and exhibiting at least 150 percent basal insulin secretion in response to 16.7 milliMolar glucose challenge in Krebs-Ringer physiological solution at pH 7.4 after said period of one month;

wherein said microcapsule comprises a polysaccharide gum surrounded by a semipermeable membrane;

and wherein said microcapsule has a diameter of from about 300 μm to about 700 μm .

PCT/US2002/012302